Shots:

• The companies collaborated to evaluate datopotamab deruxtecan + Keytruda vs Keytruda alone in P-III TROPION-Lung08 trial in ~740 patients with PD-L1 high advanced or metastatic NSCLC without actionable genomic alterations over multiple sites in Asia- EU- North & South America
• The 1EPs of a trial are PFS & OS. Additionally- the second clinical trial collaboration is based on the results in an ongoing P-Ib study
• In Jul’20- Daiichi Sankyo has entered into a collaboration with AstraZeneca to develop and commercialize datopotamab deruxtecan except in Japan. Daiichi Sankyo maintains exclusive rights  & is responsible for the manufacturing & supply of datopotamab deruxtecan

 ­ Ref: Businesswire | Image: Daiichi Sankyo